Location: Oslo (Ullernchausséen 64) About Ultimovacs Ultimovacs is a clinical-stage biotechnology company developing novel immunotherapies against cancer. Our lead product […]
Other News |
Press Releases
Interview with Carlos – ABGSC Investor Days 8 mars 2022
Enter the interview here
Biostock Article: Wave of positive momentum in 2022
Ultimovacs to ride wave of positive momentum in 2022 Ultimovacs’ Q4 report has been released and it reflects the company’s […]
Biostock article: Ultimovacs progresses to last cohort in TENDU study
“Ultimovacs continues to progress with its phase I TENDU study testing the company’s TET cancer vaccine platform in prostate cancer […]
Presentation at Redeye Fight Cancer
On January 20th, our CEO Carlos de Sousa participated at Redeye #FightCancer Outlook 2022 with some of the leading #Nordicbiotech […]
Company update on Ultimovacs after the expansion of new indication, has been published by Edison Investment Research
“Ultimovacs has made the decision to expand its R&D pipeline with a new indication, non-small cell lung cancer (NSCLC), for […]
Biostock article: “Ultimovacs’ UV1 granted orphan drug designation”
“Ultimovacs has announced being granted Orphan Drug Designation by the FDA for its universal cancer vaccine UV1 in the treatment […]
Biostock interview: “Ultimovacs reaches key milestones with UV1”
“Norwegian Ultimovacs has made some big announcements recently, including discussions for a fifth phase II clinical trial with universal cancer […]
Biostock article: “Ultimovacs launches fifth phase II trial with UV1”
“Norwegian Ultimovacs continues to expand its clinical development pipeline with universal cancer vaccine UV1. This week, the company announced its […]
HealthTalk article: “Ultimovacs tester ut prostakreftvaksine utviklet på ny kreftvaksineplattform”
“Ultimovacs jakter nå på nye kreftvaksinekandidater basert på en innovativ, ny vaksineteknologi. Norske pasienter som har fått tilbakefall etter at […]